NK042 clinical trials
Also written NK042.
How each study uses NK042 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NK042 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NK042
- 3
Studies by the year they started
3 studies that test it; most in 2024 (1)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
The Affiliated Hospital of Xuzhou Medical University (1) · Anhui Provincial Hospital (1) · Shanghai NK Cell Technology Co., LTD (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test NK042.
- Dec 2026A Phase I Study of NK042 Cell Injection in Advanced Solid TumorsPhase 1 · Shanghai NK Cell Technology Co., LTD
Studies
Open first, then newest update. How each study uses NK042 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).Not yet recruitingEarly Phase 1The Affiliated Hospital of Xuzhou Medical UniversityNCT07546110Written as NK042How we know
- A Phase I Study of NK042 Cell Injection in Advanced Solid TumorsRecruitingPhase 1Shanghai NK Cell Technology Co., LTDNCT06773091Written as NK042How we know
- A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant AscitesNot yet recruitingPhase 1Anhui Provincial HospitalNCT06415500Written as NK042How we know